Super-Responders in Moderate–Severe Psoriasis under Guselkumab Treatment Myths, Realities and Future Perspectives

A fast skin clearance is the main goal to achieve in psoriasis treatment. Patients that present a fast and exceptional improvement with treatment are called super-responders (SR). There is no consensus on the definition of SR with respect to psoriasis. Included herein is a retrospective analysis of...

Descripción completa

Detalles Bibliográficos
Autores: Ruíz Villaverde, Ricardo, Vasquez Chinchay, Fiorella, Rodríguez Fernández-Freire, Lourdes, Armario Hita, José Carlos, Pérez Gil, Amalia, Galán Gutiérrez, Manuel
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Institución:Universidad de Sevilla (US)
Repositorio:idUS. Depósito de Investigación de la Universidad de Sevilla
OAI Identifier:oai:idus.us.es:11441/146865
Acceso en línea:https://hdl.handle.net/11441/146865
https://doi.org/10.3390/life12091412
Access Level:acceso abierto
Palabra clave:guselkumab
psoriasis
super-responder
id ES_c2cd3e66eaee214111e2ea425d043bcb
oai_identifier_str oai:idus.us.es:11441/146865
network_acronym_str ES
network_name_str España
repository_id_str
spelling Super-Responders in Moderate–Severe Psoriasis under Guselkumab Treatment Myths, Realities and Future PerspectivesRuíz Villaverde, RicardoVasquez Chinchay, FiorellaRodríguez Fernández-Freire, LourdesArmario Hita, José CarlosPérez Gil, AmaliaGalán Gutiérrez, Manuelguselkumabpsoriasissuper-responderA fast skin clearance is the main goal to achieve in psoriasis treatment. Patients that present a fast and exceptional improvement with treatment are called super-responders (SR). There is no consensus on the definition of SR with respect to psoriasis. Included herein is a retrospective analysis of a multicenter, observational study of real clinical practices including patients with moderate-to-severe plaque PSO undergoing treatment with Guselkumab (GUS). This cross-sectional analysis includes information on patients between February 2019 to February 2022. A SR is a patient that achieved a PASI = 0 at weeks 12 and 24. Analyses have been performed “as observed” using GraphPad Prism version 8.3.0 for Windows (GraphPad Software, San Diego, CA, USA, At baseline, the PASI is significantly correlated with VAS_pruritus, BSA, and DLQI, while DLQI is significantly correlated with VAS_pruritus. Significant correlations increase in number and magnitude over the follow-up time. In relation to the univariate logistic models carried out, only three variables showed a significant association with the super-responder variable: depression, VAS_pruritus, and DLQI.SR patients, who show a faster evolution in PASI and BSA improvement than non-SRs. Based on the results obtained, it would be possible to also include DLQI and VAS_pruritus in the broader concept of the SR.MDPIMedicina2022info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttps://hdl.handle.net/11441/146865https://doi.org/10.3390/life12091412reponame:idUS. Depósito de Investigación de la Universidad de Sevillainstname:Universidad de Sevilla (US)InglésLife, 12 (9), 1412.https://www.mdpi.com/2075-1729/12/9/1412info:eu-repo/semantics/openAccessoai:idus.us.es:11441/1468652026-06-17T12:51:07Z
dc.title.none.fl_str_mv Super-Responders in Moderate–Severe Psoriasis under Guselkumab Treatment Myths, Realities and Future Perspectives
title Super-Responders in Moderate–Severe Psoriasis under Guselkumab Treatment Myths, Realities and Future Perspectives
spellingShingle Super-Responders in Moderate–Severe Psoriasis under Guselkumab Treatment Myths, Realities and Future Perspectives
Ruíz Villaverde, Ricardo
guselkumab
psoriasis
super-responder
title_short Super-Responders in Moderate–Severe Psoriasis under Guselkumab Treatment Myths, Realities and Future Perspectives
title_full Super-Responders in Moderate–Severe Psoriasis under Guselkumab Treatment Myths, Realities and Future Perspectives
title_fullStr Super-Responders in Moderate–Severe Psoriasis under Guselkumab Treatment Myths, Realities and Future Perspectives
title_full_unstemmed Super-Responders in Moderate–Severe Psoriasis under Guselkumab Treatment Myths, Realities and Future Perspectives
title_sort Super-Responders in Moderate–Severe Psoriasis under Guselkumab Treatment Myths, Realities and Future Perspectives
dc.creator.none.fl_str_mv Ruíz Villaverde, Ricardo
Vasquez Chinchay, Fiorella
Rodríguez Fernández-Freire, Lourdes
Armario Hita, José Carlos
Pérez Gil, Amalia
Galán Gutiérrez, Manuel
author Ruíz Villaverde, Ricardo
author_facet Ruíz Villaverde, Ricardo
Vasquez Chinchay, Fiorella
Rodríguez Fernández-Freire, Lourdes
Armario Hita, José Carlos
Pérez Gil, Amalia
Galán Gutiérrez, Manuel
author_role author
author2 Vasquez Chinchay, Fiorella
Rodríguez Fernández-Freire, Lourdes
Armario Hita, José Carlos
Pérez Gil, Amalia
Galán Gutiérrez, Manuel
author2_role author
author
author
author
author
dc.contributor.none.fl_str_mv Medicina
dc.subject.none.fl_str_mv guselkumab
psoriasis
super-responder
topic guselkumab
psoriasis
super-responder
description A fast skin clearance is the main goal to achieve in psoriasis treatment. Patients that present a fast and exceptional improvement with treatment are called super-responders (SR). There is no consensus on the definition of SR with respect to psoriasis. Included herein is a retrospective analysis of a multicenter, observational study of real clinical practices including patients with moderate-to-severe plaque PSO undergoing treatment with Guselkumab (GUS). This cross-sectional analysis includes information on patients between February 2019 to February 2022. A SR is a patient that achieved a PASI = 0 at weeks 12 and 24. Analyses have been performed “as observed” using GraphPad Prism version 8.3.0 for Windows (GraphPad Software, San Diego, CA, USA, At baseline, the PASI is significantly correlated with VAS_pruritus, BSA, and DLQI, while DLQI is significantly correlated with VAS_pruritus. Significant correlations increase in number and magnitude over the follow-up time. In relation to the univariate logistic models carried out, only three variables showed a significant association with the super-responder variable: depression, VAS_pruritus, and DLQI.SR patients, who show a faster evolution in PASI and BSA improvement than non-SRs. Based on the results obtained, it would be possible to also include DLQI and VAS_pruritus in the broader concept of the SR.
publishDate 2022
dc.date.none.fl_str_mv 2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/11441/146865
https://doi.org/10.3390/life12091412
url https://hdl.handle.net/11441/146865
https://doi.org/10.3390/life12091412
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Life, 12 (9), 1412.
https://www.mdpi.com/2075-1729/12/9/1412
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv reponame:idUS. Depósito de Investigación de la Universidad de Sevilla
instname:Universidad de Sevilla (US)
instname_str Universidad de Sevilla (US)
reponame_str idUS. Depósito de Investigación de la Universidad de Sevilla
collection idUS. Depósito de Investigación de la Universidad de Sevilla
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869418718780456960
score 15,300724

Similares en LA Referencia